CBST has guided TSRX acquisition will be accretive in 2015. I think approval of tedizolid in ABSSSI will definitely reduce the risk of eventual approval in pneumonia (HABP/VABP) - ph3 trials in this indication to start soon. It makes CBST a very attractive specialty pharma IMO.
Market Data 
Markets 
AI
